Browse YES1

Summary
SymbolYES1
NameYES proto-oncogene 1, Src family tyrosine kinase
Aliases Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location18p11.31-p11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, cytosol. Note=Newly synthesized protein initially accumulates in the Golgi region and traffics to the plasma membrane through the exocytic pathway.
Domain PF07714 Protein tyrosine kinase
PF00017 SH2 domain
PF00018 SH3 domain
Function

Non-receptor protein tyrosine kinase that is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation. Stimulation by receptor tyrosine kinases (RTKs) including EGRF, PDGFR, CSF1R and FGFR leads to recruitment of YES1 to the phosphorylated receptor, and activation and phosphorylation of downstream substrates. Upon EGFR activation, promotes the phosphorylation of PARD3 to favor epithelial tight junction assembly. Participates in the phosphorylation of specific junctional components such as CTNND1 by stimulating the FYN and FER tyrosine kinases at cell-cell contacts. Upon T-cell stimulation by CXCL12, phosphorylates collapsin response mediator protein 2/DPYSL2 and induces T-cell migration. Participates in CD95L/FASLG signaling pathway and mediates AKT-mediated cell migration. Plays a role in cell cycle progression by phosphorylating the cyclin-dependent kinase 4/CDK4 thus regulating the G1 phase. Also involved in G2/M progression and cytokinesis.

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002431 Fc receptor mediated stimulatory signaling pathway
GO:0002433 immune response-regulating cell surface receptor signaling pathway involved in phagocytosis
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0003013 circulatory system process
GO:0003018 vascular process in circulatory system
GO:0006909 phagocytosis
GO:0007159 leukocyte cell-cell adhesion
GO:0008015 blood circulation
GO:0008643 carbohydrate transport
GO:0008645 hexose transport
GO:0015749 monosaccharide transport
GO:0015758 glucose transport
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0031294 lymphocyte costimulation
GO:0031295 T cell costimulation
GO:0032526 response to retinoic acid
GO:0036119 response to platelet-derived growth factor
GO:0036120 cellular response to platelet-derived growth factor stimulus
GO:0038083 peptidyl-tyrosine autophosphorylation
GO:0038093 Fc receptor signaling pathway
GO:0038094 Fc-gamma receptor signaling pathway
GO:0038096 Fc-gamma receptor signaling pathway involved in phagocytosis
GO:0042110 T cell activation
GO:0043114 regulation of vascular permeability
GO:0045785 positive regulation of cell adhesion
GO:0046777 protein autophosphorylation
GO:0048013 ephrin receptor signaling pathway
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0050900 leukocyte migration
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071229 cellular response to acid chemical
GO:0071300 cellular response to retinoic acid
GO:0071396 cellular response to lipid
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0071593 lymphocyte aggregation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
Molecular Function GO:0004713 protein tyrosine kinase activity
GO:0004715 non-membrane spanning protein tyrosine kinase activity
GO:0005154 epidermal growth factor receptor binding
GO:0044325 ion channel binding
GO:0070851 growth factor receptor binding
Cellular Component GO:0005884 actin filament
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0009898 cytoplasmic side of plasma membrane
GO:0015629 actin cytoskeleton
GO:0019897 extrinsic component of plasma membrane
GO:0019898 extrinsic component of membrane
GO:0030055 cell-substrate junction
GO:0031234 extrinsic component of cytoplasmic side of plasma membrane
GO:0098552 side of membrane
GO:0098562 cytoplasmic side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04520 Adherens junction
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-422475: Axon guidance
R-HSA-389356: CD28 co-stimulation
R-HSA-389513: CTLA4 inhibitory signaling
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-388841: Costimulation by the CD28 family
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1266738: Developmental Biology
R-HSA-2682334: EPH-Ephrin signaling
R-HSA-3928665: EPH-ephrin mediated repulsion of cells
R-HSA-3928663: EPHA-mediated growth cone collapse
R-HSA-3928662: EPHB-mediated forward signaling
R-HSA-2029481: FCGR activation
R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-210990: PECAM1 interactions
R-HSA-1433559: Regulation of KIT signaling
R-HSA-912631: Regulation of signaling by CBL
R-HSA-162582: Signal Transduction
R-HSA-1227986: Signaling by ERBB2
R-HSA-449147: Signaling by Interleukins
R-HSA-1433557: Signaling by SCF-KIT
Summary
SymbolYES1
NameYES proto-oncogene 1, Src family tyrosine kinase
Aliases Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location18p11.31-p11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between YES1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolYES1
NameYES proto-oncogene 1, Src family tyrosine kinase
Aliases Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location18p11.31-p11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of YES1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 3 Resistant to T-cell proliferation
Summary
SymbolYES1
NameYES proto-oncogene 1, Src family tyrosine kinase
Aliases Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location18p11.31-p11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of YES1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2740.336
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6030.737
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0290.981
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0440.914
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2790.875
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4610.851
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0050.99
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2590.882
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2950.877
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1520.895
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9880.553
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1120.191
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of YES1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolYES1
NameYES proto-oncogene 1, Src family tyrosine kinase
Aliases Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location18p11.31-p11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of YES1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolYES1
NameYES proto-oncogene 1, Src family tyrosine kinase
Aliases Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location18p11.31-p11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of YES1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by YES1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolYES1
NameYES proto-oncogene 1, Src family tyrosine kinase
Aliases Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location18p11.31-p11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of YES1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolYES1
NameYES proto-oncogene 1, Src family tyrosine kinase
Aliases Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location18p11.31-p11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of YES1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolYES1
NameYES proto-oncogene 1, Src family tyrosine kinase
Aliases Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location18p11.31-p11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between YES1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolYES1
NameYES proto-oncogene 1, Src family tyrosine kinase
Aliases Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location18p11.31-p11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting YES1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting YES1.
ID Name Drug Type Targets #Targets
DB01254DasatinibSmall MoleculeABL1, ABL2, BCR, BTK, CSK, EPHA2, EPHA5, EPHB4, FGR, FRK, FYN, HSP ......22